Zheli Biotechnology

Zheli Biotechnology is a clinical-stage biopharmaceutical company based in Hangzhou, China, dedicated to developing innovative cell therapies for the treatment of solid tumors. The company leverages its proprietary Z-CAR platform to engineer CAR-T and TCR-T cells designed to overcome the immunosuppressive tumor microenvironment and enhance therapeutic persistence. Its lead program, ZL-001, is a GPC3-targeted CAR-T therapy currently in Phase 1 clinical development for hepatocellular carcinoma. Additionally, Zheli is advancing a pipeline of candidates targeting Claudin 18.2 and Mesothelin for various gastrointestinal and solid malignancies. Founded by a team of scientists from Zhejiang University, the company is focused on providing effective and accessible immunotherapy solutions for cancer patients. Zheli Biotechnology is supported by prominent venture capital firms, including Qiming Venture Partners.